Effect of Methoxsalen Photochemotherapy on Cost of Treatment for Psoriasis
- 15 May 1981
- journal article
- research article
- Published by American Medical Association (AMA)
- Vol. 245 (19) , 1913-1918
- https://doi.org/10.1001/jama.1981.03310440013015
Abstract
In 1974 a new therapy that employs methoxsalen and ultraviolet A irradiation (PUVA) was introduced as an outpatient treatment for severe psoriasis. To study the effect of this therapy on the cost of treatment, we documented for 1,320 patients two major components of cost—hospitalization and PUVA treatments. When the one-year period before initiation of PUVA therapy was compared with a one-year period after initiation of PUVA therapy, average hospital days per person per year declined 77% (5.1 vs 1.2). This decrease in hospitalization was most notable among patients who continued to use PUVA therapy. Largely offsetting the reduction in cost from reduced hospitalization was the cost of PUVA treatments. Our data confirm the previously known effectiveness of PUVA therapy, and they provide no support for the hypothesis that PUVA substantially increases the cost of treating patients with severe psoriasis. (JAMA1981;245:1913-1918)Keywords
This publication has 3 references indexed in Scilit:
- Medical Technology: The Culprit Behind Health Care CostNursing Administration Quarterly, 1980
- Medical information storage and retrieval using preprocessed variablesComputers and Biomedical Research, 1978
- Evaluation of PUVA, topical corticosteroids and the combination of both in the treatment of psoriasisBritish Journal of Dermatology, 1978